This is a phase 2 double-blind, placebo-controlled trial to test the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in participants with C9orf72-associated Amyotrophic Lateral Sclerosis.
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.